Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis

BACKGROUND: Rituximab (RTX) has been previously reported as directed treatment in patients with connective-tissue disease-related interstitial lung diseases (CTD-ILD). A systematic assessment of treatment effect size on pulmonary function outcomes and related adverse effects in patients with CTD-ILD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yuanchen, Gao, Yang, Petnak, Tananchai, Cheungpasitporn, Wisit, Thongprayoon, Charat, Zhang, Xing, Moua, Teng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215101/
https://www.ncbi.nlm.nih.gov/pubmed/35729565
http://dx.doi.org/10.1186/s12931-022-02082-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215101/
https://www.ncbi.nlm.nih.gov/pubmed/35729565
http://dx.doi.org/10.1186/s12931-022-02082-x

Ejemplares similares